Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-15
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Phase:
PHASE2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou Overseas Chinese Hospital,Guangdong